Washington D.C. /
The United States Food and Drug Administration (FDA) granted emergency approval for a treatment with synthetic antibodies against the company’s covid-19 Regeneron which was used to treat President Donald Trump when he contracted the coronavirus.
“Licensing these monoclonal antibody therapies can help outpatients avoid being hospitalized and ease the burden on our healthcare system,” he said. Stephen Hahn, Commissioner of the FDA.
The FDA said monoclonal antibodies, casirivimab e imdevimab, should be administered together for the treatment of covid-19 mild to moderate in adult patients and children with positive results of the direct viral test for covid-19 and who have a high risk of progression. This includes those who are 65 years of age or older or who have certain chronic medical conditions.
They affirmed said that this type of antibodies are not authorized for patients who are hospitalized or who require oxygen therapy due to covid-19. They said that no benefit of treatment with casirivimab e imdevimab in hospitalized patients due to SARS-CoV-2.
*The article has been translated based on the content of Source link by https://www.milenio.com/internacional/estados-unidos/eu-aprueba-tratamiento-regeneron-atender-covid-19
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!